



# **MO HEALTHNET PHARMACY PROGRAM NEW DRUGS AND EDITS WITH NO ANNUAL CHANGES**

**MHD PA COMMITTEE SEPTEMBER 15, 2022  
OLIVIA RUSH, PHARM D – PROGRAM INTEGRITY PHARMACIST**

# NEW DRUGS – CLINICAL EDITS

Common Trade Name	Ingredient Name	Indications
Amvuttra 25mg/0.5ml Syringe	Vutrisiran Sodium	Indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults. <b>Transthyretin-Mediated Amyloidosis (ATTR) Clinical Edit – To be discussed today</b>
Camzyos 2.5mg Capsule Camzyos 5mg Capsule Camzyos 10mg Capsule Camzyos 15mg Capsule	Mavacamten	Indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms. <b>Camzyos Clinical Edit</b> • <b>Dose opt of 1 capsule per day</b>
Vioice 50mg Tablet Vioice 125mg Tablet Vioice 250mg Dose Pack	Alpelisib	Indicated for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy. <b>Alpelisib Clinical Edit – To be discussed today</b>

# NEW DRUGS – PDL EDITS

Common Trade Name	Ingredient Name	Indications
Adlarity 5mg/Day Patch Adlarity 10mg/Day Patch	Donepezil HCL	Indicated for the treatment of mild, moderate, and severe dementia of the Alzheimer's type. <b>Alzheimer's Agents, Acetylcholinesterase Inhibitors, N-Methyl-D-Aspartate Receptor Antagonists and Combinations PDL Edit – Non-Preferred</b>
Camcevi 42mg Syringe	Leuprolide Mesylate	Indicated for the treatment of adult patients with advanced prostate cancer. <b>Luteinizing Hormone Releasing Hormone (LHRH)/Gonadotropin Releasing Hormone (GnRH) Agents, Non-Oral PDL Edit – Non-Preferred – To be discussed today</b>
Lyvispah 5mg Granule Packet Lyvispah 10 mg Granule Packet Lyvispah 20mg Granule Packet	Baclofen	Indicated for the treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. <b>Skeletal Muscle Relaxants PDL Edit – Non-Preferred</b> <b>Prior Authorization Required Fiscal Edit</b> <ul style="list-style-type: none"> <li>• <b>Must provide a letter of medical necessity as to why participant cannot use the baclofen solution.</b></li> </ul>
Mounjaro 2.5mg/0.5ml Pen Mounjaro 5mg/0.5ml Pen Mounjaro 7.5mg/0.5ml Pen Mounjaro 10mg/0.5ml Pen Mounjaro 12.5mg/0.5ml Pen Mounjaro 15mg/0.5ml Pen	Tirzepatide	Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. <b>Glucagon-Like Peptide -1 (GLP-1) Receptor Agonists &amp; Combination Agents PDL Edit – Non-Preferred – To be discussed today</b>

# NEW DRUGS – PDL EDITS

Common Trade Name	Ingredient Name	Indications
Norliqva 1mg/ml Solution	Amlodipine Besylate	Indicated for the treatment of hypertension in adults and children 6 years of age and older and for coronary artery disease. <b>Calcium Channel Blockers, Dihydropyridine PDL Edit – Non-Preferred – To be discussed today</b> <ul style="list-style-type: none"> <li>• <b>Participants ≥ 10 years of age - must provide a letter of medical necessity as to why participant cannot use the amlodipine tablets.</b></li> </ul>
Nucala 40mg/0.4ml Syringe	Mepolizumab	Indicated for the treatment of severe eosinophilic asthma in children 6 to 11 years of. <b>Targeted Immune Modulators, Misc. Allergy and Asthma Related Monoclonal Antibodies PDL Edit – Non-Preferred – To be discussed today</b>
Olumiant 4mg Tablet	Baricitinib	Indicated for the treatment of adult patients with severe alopecia areata. <b>Targeted Immune Modulators, Janus Kinase (JAK) Inhibitors PDL Edit – Non-Preferred – To be discussed today</b>
Ozempic 2mg/0.75ml Pen	Semaglutide	Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease. <b>Glucagon-Like Peptide -1 (GLP-1) Receptor Agonists &amp; Combination Agents PDL Edit – Non-Preferred – To be discussed today</b>

# NEW DRUGS – PDL EDITS

Common Trade Name	Ingredient Name	Indications
Skyrizi 360mg/2.4ml On Body Skyrizi 600mg/10ml Vial	Risankizumab-Rzaa	Indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. <b>Targeted Immune Modulators, IL-23 Inhibitors and IL-23/IL-12 Inhibitors PDL Edit – Non-Preferred – To be discussed today</b>
Tlando 112.5mg Capsule	Testosterone Undecanoate	Indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. <b>Androgenic Agents PDL Edit – Non-Preferred</b>
Triumeq PD 60-5-30mg Tablet for Oral Suspension	Abacavir/Dolutegravir/Lamivudine	Indicated for the treatment of HIV-1 infection in adults and in pediatric patients weighing at least 10 kg. <b>Antiretroviral Therapy (ART) PDL Edit – Group A – Preferred</b>
Tyvaso DPI 16mcg Cartridge Tyvaso DPI 16-32mcg Titr Kit Tyvaso DPI 16-32-48mcg Titr Tyvaso DPI 32mcg Cartridge Tyvaso DPI 32-48 Maint Kit Tyvaso DPI 48mcg Cartridge Tyvaso DPI 64mcg Cartridge	Treprostinil	Indicated for the treatment of: <ul style="list-style-type: none"> <li>• Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability</li> <li>• Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability</li> </ul> <b>Pulmonary Arterial Hypertension (PAH) Agents, Prostacyclin Pathway Agonists, Inhaled PDL Edit – Non-Preferred – To be discussed today</b>

# NEW DRUGS – OPEN ACCESS

Common Trade Name	Ingredient Name	Indications
Beovu 6mg/0.05ml Syringe	Brolucizumab-dblI	Indicated for the treatment of: <ul style="list-style-type: none"><li>• Neovascular (Wet) Age-related Macular Degeneration (AMD)</li><li>• Diabetic Macular Edema (DME)</li></ul>
Byooviz 0.5mg/0.05ml Vial	Ranibizumab-Nuna	Indicated for the treatment of: <ul style="list-style-type: none"><li>• Neovascular (Wet) Age-related Macular Degeneration (AMD)</li><li>• Macular edema following retinal vein occlusion</li><li>• Myopic Choroidal Neovascularization</li></ul>
Radicava ORS 105mg/5ml Suspension	Edaravone	Indicated for the treatment of amyotrophic lateral sclerosis (ALS).

# NEW DRUGS – STEP THERAPY

Common Trade Name	Ingredient Name	Indications
Epsolay 5% Cream Pump	Benzoyl Peroxide	Indicated for the treatment of inflammatory lesions of rosacea in adults. <b>Acne and Rosacea - Select Topical Agents Step Therapy Edit</b> <b>High Cost Therapy within the Acne and Rosacea Step Therapy Edit</b>

# CLINICAL & FISCAL EDITS WITH NO ANNUAL CHANGES

- ▶ Entresto Clinical Edit
- ▶ Spinal Muscular Atrophy (SMA) Clinical Edit



# PDL EDITS WITH NO ANNUAL CHANGES

- ▶ ACE-Inhibitors and ACE-Inhibitors/Diuretic Combinations
- ▶ ACE-Inhibitors/Calcium Channel Blocker Combinations
- ▶ ADHD, Methylphenidate, Short Acting
- ▶ ADHD, Non-Stimulants
- ▶ Alpha-Glucosidase Inhibitors
- ▶ Amylin Analogs
- ▶ Antibiotics, Mupirocin Topical
- ▶ Antihyperuricemic Agents
- ▶ ARBs and ARBs/Diuretic Combinations
- ▶ ARBs/Calcium Channel Blocker Combinations
- ▶ Benign Prostatic Hyperplasia (BPH) Agents
- ▶ Beta Blockers & Beta Blockers/Diuretic Combinations
- ▶ Biguanides & Combinations
- ▶ Bone Ossification Agents
- ▶ Calcium Channel Blockers, Non-Dihydropyridines
- ▶ Cephalosporin Agents
- ▶ Direct Renin Inhibitors & Combinations
- ▶ DPP-IV Inhibitors & Combinations
- ▶ Electrolyte Depleting Agents, Phosphate Lowering
- ▶ Erythropoiesis Stimulating Agents
- ▶ Fluoroquinolone Agents, Oral

# PDL EDITS WITH NO ANNUAL CHANGES CONTINUED

- ▶ Fluoroquinolone Agents, Oral
- ▶ Homozygous Familial Hypercholesterolemia (HoFH) Agents
- ▶ Insulin, Mixed
- ▶ Insulin, Non-Analogs
- ▶ Insulin, Rapid Acting
- ▶ Macrolides
- ▶ Meglitinides
- ▶ Methotrexate Agents
- ▶ Niacin Derivatives
- ▶ Pulmonary Arterial Hypertension (PAH) Agents, Endothelin Receptor Antagonists (ETRAAs)
- ▶ Pulmonary Arterial Hypertension (PAH) Agents, PDE5-Inhibitors and SGC Stimulators
- ▶ Pulmonary Arterial Hypertension (PAH) Agents, Prostacyclins, Oral
- ▶ Penicillin Agents
- ▶ Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors & Combination Agents
- ▶ Statins (HMG-CoA Reductase Inhibitors) & Combinations
- ▶ Sulfonylureas, Second Generation
- ▶ Tetracycline Agents
- ▶ Thiazolidinediones & Combinations
- ▶ Thrombocytopenia Agents
- ▶ Triglyceride Lowering Agents